Clinician’s Report: Infection Control Products

Eloquest Healthcare, Inc.

Hospital Subsidiary of the Ferndale Pharma Group, Ferndale, MI
www.eloquesthealthcare.com • (877) 433-7626
information@eloquesthealthcare.com • Founded: 2008 (Parent Company: 1897)

1) How long has your company been making products that protect against the risk of infection for use in wound care clinics? We have manufactured infection care products since the 1940s, when Ferndale Laboratories (now known as Ferndale Pharma Group) introduced Detachol® Adhesive Remover. Detachol aids in the removal of tapes and dressings to mitigate the risk of skin tears that can compromise the skin barrier and lead to infection.

2) List the categor(ies) of products your company promotes. Our product categories include liquid adhesives (Mastisol®), adhesive removers (Detachol®), and advanced wound care products (Microcyn® Rx Skin and Wound Care with Preservatives Solution).

3) What sets your products apart from others in the market today? We provide simple-to-use, cost-effective dermal solutions.

4) What advice do you have for wound care clinicians interested in purchasing infection control products for the clinic? Consider products that minimize the risk of infection development. Doing so can result in improved patient outcomes, minimized costs and risks, and possibly in lives saved.

5) What is your newest addition to your wound care product line? Eloquest Healthcare has recently partnered with Oculus Innovative Sciences to support its Microcyn® product line in the acute care market, with a major emphasis on communicating the benefits of Microcyn® Rx, Skin and Wound Care Solution with Preservatives.

6) What are some unique features and benefits of this product? The product has several important benefits. The preservatives sodium hypochlorite and hypochlorous acid prevent contamination of solution during repeat use and demonstrates in vitro activity against a broad range of Gram-negative, Gram-positive, and yeast species in just 30 seconds. The product’s pH-neutral, water-based solution (99.97% water) is noncytotoxic, nonirritating, nonsensitizing, and nontoxic to the wound bed; has proven efficacy to reduce wound odor; does not confer antibiotic resistance; does not require preparation or rinsing; and does not represent a biohazard risk or disposal cost.

7) Have you noticed any changes or trends in the area of infection control lately that our readers would find beneficial for their practice? More emphasis has been placed on ensuring positive patient outcomes and creating initiatives that focus on reducing preventable medical errors, including but not limited to, reduction of hospital-acquired infections (HAIs). Ultimately, this results in better patient outcomes as well as in cost savings for the hospital.

8) Why do your company officials believe infection control/prevention is so important for the healthcare industry? The fifth leading cause of death in the U.S. is HAI. Even though they are preventable, HAIs are estimated to kill more than 90,000 people per year while adding more than $5 billion in excess costs to our healthcare system. Now that hospitals no longer get Medicare and Medicaid reimbursement for certain preventable injuries, it has become paramount for clinicians to evaluate ways they can minimize the risk of HAIs at their institutions.

9) How can prospective customers get more information on this product? Call us toll free: (877) 433-7626; email: information@eloquesthealthcare.com, or visit: www.eloquesthealthcare.com.